Form 4: Beam Therapeutics CEO Sells Shares Under 10b5-1 Plan

Beam Therapeutics CEO John M. Evans sold 50,000 shares of common stock for over $1.2 million through a pre-arranged 10b5-1 trading plan.

Summary

• John M. Evans, CEO and Director of Beam Therapeutics Inc. (BEAM), reported transactions involving the company's common stock.
• On October 1, 2025, Mr. Evans exercised options to acquire 25,000 shares at $0.67 per share and subsequently sold these 25,000 shares at a weighted average price of $24.5062 per share.
• On October 2, 2025, he again exercised options to acquire 25,000 shares at $0.67 per share and sold these 25,000 shares at a weighted average price of $24.6267 per share.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on May 16, 2025.
• Following these transactions, Mr. Evans directly beneficially owns 986,667 shares of common stock.
• He also indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust.
• Additionally, 418 shares were acquired by Mr. Evans under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025.

Sentiment

Score: 5

Explanation: The transactions represent routine insider sales executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to manage personal finances and diversify holdings. It does not inherently signal a positive or negative outlook on the company's future.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, adopted on May 16, 2025, which indicates planned personal financial management rather than opportunistic selling.
• The transactions allowed the CEO to monetize vested stock options, providing personal liquidity.

Negatives

• The transactions resulted in a reduction of John M. Evans' direct beneficial ownership of Beam Therapeutics common stock by 50,000 shares.
• Insider sales, even under a 10b5-1 plan, can sometimes be viewed with caution by investors, though the pre-scheduled nature mitigates this concern.

Future Outlook

No forward-looking statements or guidance were provided in this Form 4 filing.

Industry Context

Form 4 filings are routine for corporate insiders, detailing changes in their beneficial ownership. These sales, executed under a Rule 10b5-1 trading plan, are a common practice for executives to manage personal liquidity and diversify their investment portfolios in a compliant manner, reducing concerns about opportunistic trading.

Comparison to Industry Standards

• This Form 4 filing is a standard disclosure for insider transactions, consistent with regulatory requirements across publicly traded companies.
• The use of a Rule 10b5-1 trading plan for these sales aligns with best practices for corporate executives to avoid accusations of trading on material non-public information.

Related Party Transactions

• John M. Evans indirectly owns 103,000 shares through the John M. Evans, III 2018 Irrevocable Trust, which is a related party to the reporting person.

Stakeholder Impact

• Shareholders may note the reduction in direct insider ownership, but the pre-scheduled nature of the sales under a 10b5-1 plan generally mitigates concerns about management's confidence in the company.

Key Dates

Recommendation

The filing details routine insider sales executed under a pre-arranged 10b5-1 trading plan. Such transactions are common for executives managing personal finances and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this report.

Keywords

Beam Therapeutics, BEAM, Insider Trading, Form 4, Stock Sale, CEO, John M. Evans, 10b5-1 Plan, Equity Sales, Biotechnology